Comparison of efficacy and safety of second‐ and third‐generation TKIs for non‐small‐cell lung cancer with uncommon EGFR mutations
Abstract Background The efficacy of definite for non‐small‐cell lung cancer (NSCLC) with uncommon epidermal growth factor receptor (EGFR) mutations has been preliminarily demonstrated. However, there is a paucity of data with which to compare the efficacy and safety of second‐ and third‐generation T...
Kaydedildi:
| Asıl Yazarlar: | , , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Wiley
2023-08-01
|
| Seri Bilgileri: | Cancer Medicine |
| Konular: | |
| Online Erişim: | https://doi.org/10.1002/cam4.6229 |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|